In re Clinton S.

2016 IL App (2d) 151138
CourtAppellate Court of Illinois
DecidedJuly 28, 2017
Docket2-15-1138
StatusPublished
Cited by2 cases

This text of 2016 IL App (2d) 151138 (In re Clinton S.) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Clinton S., 2016 IL App (2d) 151138 (Ill. Ct. App. 2017).

Opinion

Digitally signed by Illinois Official Reports Reporter of Decisions Reason: I attest to the accuracy and integrity of this document Appellate Court Date: 2017.07.26 14:08:22 -05'00'

In re Clinton S., 2016 IL App (2d) 151138

Appellate Court In re CLINTON S., Alleged to be a Person Subject to Involuntary Caption Administration of Psychotropic Medication (The People of the State of Illinois, Petitioner-Appellee, v. Clinton S., Respondent-Appellant).

District & No. Second District Docket No. 2-15-1138

Filed December 2, 2016 Rehearing denied March 21, 2017

Decision Under Appeal from the Circuit Court of Kane County, No. 15-MH-88; the Review Hon. Divya Sarang, Judge, presiding.

Judgment Affirmed.

Counsel on Veronique Baker, of Guardianship and Advocacy Commission, of Appeal Chicago, and Cynthia Z. Tracy, of Guardianship and Advocacy Commission, of Peoria, for appellant.

Joseph H. McMahon, State’s Attorney, of St. Charles (Patrick Delfino, Lawrence M. Bauer, and Diane L. Campbell, of State’s Attorneys Appellate Prosecutor’s Office, of counsel), for the People.

Panel JUSTICE HUTCHINSON delivered the judgment of the court, with opinion. Justices Birkett and Spence concurred in the judgment and opinion. OPINION

¶1 Respondent, Clinton S., had a long history of mental health issues. He had also been diagnosed with end-stage kidney failure. In granting a petition for the involuntary administration of psychotropic medication pursuant to section 2-107.1 of the Mental Health and Developmental Disabilities Code (Mental Health Code) (405 ILCS 5/2-107.1 (West 2014)), the trial court also ordered that respondent undergo regular hemodialysis treatments. This was based on evidence that hemodialysis was essential for the safe and effective administration of the medication, as respondent’s kidneys could not otherwise filter the chemicals from his blood. Respondent appeals, arguing that (1) the State failed to prove by clear and convincing evidence that the benefits of the medication outweighed the harm, and (2) the trial court’s order exceeded the scope of the testing and other procedures that are authorized under section 2-107.1. We affirm.

¶2 I. BACKGROUND ¶3 Respondent was admitted to the Elgin Mental Health Center (EMHC) on February 5, 2015, after being found unfit to stand trial on a robbery charge. He had been hospitalized for issues related to his mental health over 40 times since 1980. At the time of these proceedings, respondent was 53 years old. ¶4 On July 23, 2015, the State filed a petition for the involuntary administration of psychotropic medication pursuant to section 2-107.1 of the Mental Health Code. Dr. Mirella Susnjar signed the petition as respondent’s treating psychiatrist. In addition to seeking the involuntary administration of several medications, Susnjar requested that respondent be ordered to undergo regular hemodialysis treatments, which she deemed essential for the safe and effective administration of the requested medications. Susnjar noted that respondent was suffering from end-stage kidney failure, and she asserted that hemodialysis was necessary to prolong his life.1 ¶5 The trial court conducted a hearing on the petition on August 21, 2015. Susnjar was the only witness to testify. The parties stipulated that Susnjar was an expert in the field of psychiatry. Susnjar testified that she had performed a psychiatric evaluation on respondent and had diagnosed him with schizophrenia. Susnjar explained that respondent suffered hallucinations and delusions, heard voices, talked to himself, and struggled to converse with other people. Respondent also occasionally became angry and violent. In one instance, he threw a food tray and threatened to kill a nurse. Susnjar testified that respondent’s symptoms had not improved from less restrictive treatments such as “one-to-one” and group therapies. She did not believe that respondent was likely to stabilize without psychotropic medication. She had checked respondent’s medical records and consulted with his assigned social worker, but she was unable to determine whether respondent had executed a power of attorney for health care or a declaration under the Mental Health Treatment Preference Declaration Act (755 ILCS 43/1 et seq. (West 2014)).

The Mayo Clinic website describes “hemodialysis” as a procedure used for the treatment of 1

advanced kidney failure in which a machine is used to filter wastes, salts, and fluid from the blood. Hemodialysis, Mayo Clinic, http://www.mayoclinic.org/tests-procedures/hemodialysis/home/ovc- 20229742 (last visited Nov. 3, 2016).

-2- ¶6 Susnjar testified that respondent had previously agreed to take Stelazine (trifluoperazine), Haldol (haloperidol), Benadryl (diphenhydramine), and lorazepam. When he took these medications, his symptoms improved. He was able to plan and discuss his legal and health situations. However, he eventually stopped taking the medications due to his preference for “white” Stelazine. Susnjar explained that the EMHC offered only “purple” Stelazine. Beyond the color, the medications were the same. After respondent stopped taking his medications, his symptoms returned. ¶7 To treat respondent’s mood and psychosis, Susnjar sought to administer specified doses of trifluoperazine, risperidone, quetiapine, and aripiprazole. Susnjar testified that the side effects of the medications included neuroleptic malignant syndrome, involuntary movements, lower blood pressure, sedation, muscle rigidity, tardive dyskinesia, diabetes, weight gain, and cataracts. The primary benefits of the medications were that respondent would become calm and better able to express himself and make decisions. ¶8 Susnjar also petitioned for the administration of five alternative medications: haloperidol, fluphenazine, lorazepam, diphenhydramine, and benztropine. She testified that haloperidol and fluphenazine were alternative psychotropic medications for the treatment of psychosis and delirium and that they involved similar side effects and benefits as the primary psychotropic medications. Lorazepam would be used if necessary to treat anxiety; the potential side effects were sedation and addiction. Finally, diphenhydramine and benztropine were used to treat the side effects from the psychotropic medications. The risks included weight gain, confusion, dry mouth, constipation, and difficulty urinating. ¶9 Susnjar also testified at length about respondent’s kidney disease and her request for hemodialysis treatments. She explained that respondent was admitted to Sherman Hospital for renal failure in April 2015. When respondent was discharged in May 2015, his treating nephrologist diagnosed him with end-stage kidney failure and recommended that he undergo hemodialysis treatments three times per week. Respondent initially received 18 hemodialysis treatments without incident, but he later began refusing the treatments. These refusals happened around the same time that respondent began refusing to take the psychotropic medications. Susnjar testified that she had repeatedly discussed with respondent the status of his kidneys and the need for hemodialysis, but respondent insisted that it was not necessary. Based on these facts, Susnjar opined that respondent’s mental illness was directly related to his refusal to undergo hemodialysis. Although Susnjar refrained from speculating on a specific time frame, she opined that respondent would eventually die if he did not receive hemodialysis. Susnjar further opined that the hemodialysis was necessary for the safe and effective administration of the psychotropic medications, because respondent’s kidneys could not adequately filter the chemicals from his blood.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re John F.
2022 IL App (1st) 220851 (Appellate Court of Illinois, 2022)
In re Clinton S.
2016 IL App (2d) 151138 (Appellate Court of Illinois, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
2016 IL App (2d) 151138, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-clinton-s-illappct-2017.